# iBio

Type: Company (IBIO)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/ibio
Canonical HTML page: https://getbiobrief.com/entity/ibio

## Timeline

- **2027**: IND Filing — Potential window for Investigational New Drug application with the FDA.
- **2026**: Preclinical Initiation — Start of IND-enabling studies and toxicology assessments.
- **2026-Q3**: Candidate Selection — Expected naming of the lead development candidate for the program.
- **2026-Q1**: Strategy Announcement — iBio outlines bispecific approach for PH-HFpEF.

## Recent coverage (1 stories)

### iBio Targets Q3 for Lead Bispecific Candidate in PH-HFpEF Treatment
2026-03-20 09:42:12 · Sentiment: Positive · Impact: 6/10 · Sources: 2

iBio is advancing its bispecific antibody strategy to address Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), a major unmet medical need. The company expects to select a formal development candidate by the third quarter of 2026, signaling a transition from discovery to preclinical development for its lead cardiovascular program.
Full story: https://getbiobrief.com/story/ibio-bispecific-antibody-strategy-ph-hfpef-q3-candidate

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.